- Home
- EBTC vs ATAI Comparison
EBTC vs ATAI Comparison
Compare EBTC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBTC
- ATAI
- Stock Information
- Founded
- EBTC 1989
- ATAI 2018
- Country
- EBTC United States
- ATAI Germany
- Employees
- EBTC N/A
- ATAI N/A
- Industry
- EBTC Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- EBTC Finance
- ATAI Health Care
- Exchange
- EBTC Nasdaq
- ATAI Nasdaq
- Market Cap
- EBTC 477.9M
- ATAI 444.7M
- IPO Year
- EBTC 2005
- ATAI 2021
- Fundamental
- Price
- EBTC $38.43
- ATAI $2.48
- Analyst Decision
- EBTC
- ATAI Strong Buy
- Analyst Count
- EBTC 0
- ATAI 3
- Target Price
- EBTC N/A
- ATAI $10.50
- AVG Volume (30 Days)
- EBTC 20.4K
- ATAI 2.7M
- Earning Date
- EBTC 07-22-2025
- ATAI 08-12-2025
- Dividend Yield
- EBTC 2.60%
- ATAI N/A
- EPS Growth
- EBTC 11.95
- ATAI N/A
- EPS
- EBTC 3.27
- ATAI N/A
- Revenue
- EBTC $172,242,000.00
- ATAI $1,863,000.00
- Revenue This Year
- EBTC N/A
- ATAI $554.22
- Revenue Next Year
- EBTC N/A
- ATAI N/A
- P/E Ratio
- EBTC $11.76
- ATAI N/A
- Revenue Growth
- EBTC 7.98
- ATAI 572.56
- 52 Week Low
- EBTC $22.60
- ATAI $1.03
- 52 Week High
- EBTC $44.41
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- EBTC 44.31
- ATAI 66.50
- Support Level
- EBTC $39.42
- ATAI $2.06
- Resistance Level
- EBTC $41.40
- ATAI $2.55
- Average True Range (ATR)
- EBTC 0.78
- ATAI 0.20
- MACD
- EBTC -0.20
- ATAI -0.02
- Stochastic Oscillator
- EBTC 18.18
- ATAI 72.41
About EBTC Enterprise Bancorp Inc
Enterprise Bancorp Inc is a holding company engaged in the business of gathering deposits from the general public and investing in loans and investment securities. Through the Bank and its subsidiaries, the company offers a range of commercial, residential, and consumer loan products, deposit products, and cash management services, as well as wealth management and wealth services.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.